[go: up one dir, main page]

PE20081507A1 - Derivados de pirimidina como moduladores de jnk - Google Patents

Derivados de pirimidina como moduladores de jnk

Info

Publication number
PE20081507A1
PE20081507A1 PE2007001744A PE2007001744A PE20081507A1 PE 20081507 A1 PE20081507 A1 PE 20081507A1 PE 2007001744 A PE2007001744 A PE 2007001744A PE 2007001744 A PE2007001744 A PE 2007001744A PE 20081507 A1 PE20081507 A1 PE 20081507A1
Authority
PE
Peru
Prior art keywords
pyrimidin
alkyl
ilamino
indol
halogen
Prior art date
Application number
PE2007001744A
Other languages
English (en)
Inventor
James Patrick Dunn
David Michael Goldstein
Leyi Gong
Joan Heather Hogg
Christophe Michoud
Wylie Solang Palmer
Achyutharao Sidduri
Tania Silva
Parcharee Tivitmahaisoon
Teresa Alejandra Trejo-Martin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39099641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081507(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081507A1 publication Critical patent/PE20081507A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE PIRIMIDINA DE FORMULA (I), DONDE X1 ES N, N-R3, CH3, C-R3, O; X2 ES N, NH, N-CH3, CH, CH2, ENTRE OTROS; X3 ES N, C O CH; X4 Y X5 SON C, CH O N; R ES -(CICLOHEXIL)-R2 O -(FENIL)-R8 SUSTITUIDOS OPCIONALMENTE CON METILO, FLUOR, CLORO O HIDROXI; R1 ES HALOGENO, NITRO, CN, OH, ENTRE OTROS; n ES UN ENTERO DE 0 A 2; R3 ES H O ALQUILO C1-C6; R2 ES H, OH, =O, CN, ENTRE OTROS; R8 ES H, ALQUILO C1-C6, OR3, SO2NH2, ENTRE OTROS; Z ES H, HALOGENO, ALQUILO C1-C12, NH2. SON COMPUESTOS PREFERIDOS: 4-[4-(4-BENCILOXI-INDOL-1-IL)-PIRIMIDIN-2-ILAMINO]-CICLOHEXA-NOL, 4-[4-(4-BROMOINDOL-1-IL)-PIRIMIDIN-2-ILAMINO]-CICLOHEXANOL, (2-METANOSULFONILETIL)AMIDA DEL ACIDO 4-(4-INDOL-1-IL)-PIRIMIDIN-2-ILAMINO]-CICLOHEXANOCARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCESO DE PREPARACION. DICHOS COMPUESTOS SON MODULADORES DE QUINASAS C-JUN-N-TERMINALES (JNK) Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS INMUNES, INFLAMATORIOS, NEUROLOGICAS, ENTRE OTRAS
PE2007001744A 2006-12-08 2007-12-07 Derivados de pirimidina como moduladores de jnk PE20081507A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87362506P 2006-12-08 2006-12-08

Publications (1)

Publication Number Publication Date
PE20081507A1 true PE20081507A1 (es) 2008-11-12

Family

ID=39099641

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001744A PE20081507A1 (es) 2006-12-08 2007-12-07 Derivados de pirimidina como moduladores de jnk

Country Status (18)

Country Link
US (1) US8399462B2 (es)
EP (1) EP2102194A1 (es)
JP (1) JP5179509B2 (es)
KR (1) KR101152162B1 (es)
CN (1) CN101547917A (es)
AR (1) AR064133A1 (es)
AU (1) AU2007328981B2 (es)
BR (1) BRPI0720003A2 (es)
CA (1) CA2670375A1 (es)
CL (1) CL2007003502A1 (es)
IL (1) IL198543A0 (es)
MX (1) MX2009005508A (es)
NO (1) NO20091942L (es)
PE (1) PE20081507A1 (es)
RU (1) RU2493155C2 (es)
TW (1) TW200831101A (es)
WO (1) WO2008068171A1 (es)
ZA (1) ZA200903495B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2158182A2 (en) 2007-06-15 2010-03-03 F. Hoffmann-Roche AG A novel process for the preparation of 3-amino-pentan-1,5-diol
EP2205564B1 (en) * 2007-10-23 2014-07-30 F. Hoffmann-La Roche AG Novel kinase inhibitors
CA2722158A1 (en) 2008-05-16 2009-11-19 F. Hoffmann-La Roche Ag Inhibitors of jnk
EP2379527A1 (en) * 2008-12-19 2011-10-26 F. Hoffmann-La Roche AG Pyrimidin- 2 -ylamino derivatives and their use to treat inflammation
SG173792A1 (en) 2009-02-24 2011-10-28 Hoffmann La Roche Imidazo [1, 2 -a] pyridines as jnk modulators
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
WO2011018417A1 (en) * 2009-08-10 2011-02-17 F. Hoffmann-La Roche Ag Inhibitors of jnk
NZ599041A (en) * 2009-11-13 2014-05-30 Genosco Kinase inhibitors
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2576559B1 (en) * 2010-06-04 2015-03-04 F.Hoffmann-La Roche Ag Inhibitors of jnk
MX2012013589A (es) * 2010-06-04 2012-12-17 Hoffmann La Roche Derivados de 2-amino pirimidina utiles como inhibidores de cinasas del extremo n-terminal de c-jun (jnk).
CA2826295C (en) 2011-02-04 2020-10-20 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
SG10201601802YA (en) 2011-03-10 2016-04-28 Daiichi Sankyo Co Ltd Dispiropyrrolidine derivatives
EP2822935B1 (en) 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
DK2903440T3 (en) 2012-10-02 2017-12-11 Bayer Cropscience Ag THETEROCYCLIC COMPOUNDS AS PESTICIDES
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
EP2964221B1 (en) 2013-03-04 2017-12-06 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134776A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134772A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
WO2015073344A1 (en) * 2013-11-14 2015-05-21 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
RS58175B1 (sr) 2014-04-04 2019-03-29 Syros Pharmaceuticals Inc Inhibitori ciklin-zavisne kinaze 7 (cdk7)
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2016036586A1 (en) 2014-09-03 2016-03-10 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
BR112017012272A2 (pt) * 2014-12-11 2018-01-30 Beta Pharma, Inc. derivados de 2-anilinopirimidina como moduladores de egfr
HK1245260A1 (zh) 2014-12-23 2018-08-24 Dana-Farber Cancer Institute, Inc. 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017133664A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment， amelioration or prevention of influenza
WO2017133658A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh 4, 7-diazaindole and 4, 7-diazaindazole derivatives and their use in the treatment, amelioration or prevention of influenza
AU2018283289B2 (en) 2017-06-16 2021-03-25 Beta Pharma, Inc. Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
KR102195348B1 (ko) * 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
MX2023000630A (es) * 2020-07-14 2023-03-15 Wuhan Ll Science & Technology Development Co Ltd Inhibidor de rock, y método de preparacion para el mismo y uso del mismo.
CN113563310B (zh) * 2021-06-25 2022-10-11 浙江工业大学 一种4-(1-甲基吲哚-3-基)嘧啶类衍生物及其应用
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN114790174B (zh) * 2022-04-14 2023-09-29 淮阴工学院 一种连续合成1h-吲唑类化合物的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788195A (en) * 1986-01-13 1988-11-29 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
JP2003523942A (ja) 1999-06-30 2003-08-12 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US20030004174A9 (en) * 2000-02-17 2003-01-02 Armistead David M. Kinase inhibitors
WO2001062233A2 (en) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
IL156784A0 (en) 2001-02-20 2004-02-08 Astrazeneca Ab 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
UA75392C2 (en) * 2001-02-23 2006-04-17 Merck & Co Inc N-substituted non-aryl heterocyclic antagonists nmda/nr2b
US20040171630A1 (en) * 2001-06-19 2004-09-02 Yuntae Kim Tyrosine kinase inhibitors
EP1463730B1 (en) * 2001-12-17 2006-04-19 SmithKline Beecham Corporation Pyrazolopyridazine derivatives
TW200302722A (en) 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
WO2004005283A1 (en) * 2002-07-09 2004-01-15 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
US7855205B2 (en) * 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
WO2006124863A2 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
WO2008028860A1 (en) 2006-09-08 2008-03-13 F. Hoffmann-La Roche Ag Benzotriazole kinase modulators
KR101101675B1 (ko) 2006-10-02 2011-12-30 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
CL2007002904A1 (es) 2006-10-10 2008-06-06 Amgen Inc Soc Organizada Bajo Compuestos derivados de pirazolopirimidina; composicion farmaceutica; y uso para tratar una enfermedad seleccionada de diabetes, obesidad, asma y artritis entre otras.
EP2379527A1 (en) * 2008-12-19 2011-10-26 F. Hoffmann-La Roche AG Pyrimidin- 2 -ylamino derivatives and their use to treat inflammation

Also Published As

Publication number Publication date
JP2010511655A (ja) 2010-04-15
EP2102194A1 (en) 2009-09-23
NO20091942L (no) 2009-07-07
US8399462B2 (en) 2013-03-19
CA2670375A1 (en) 2008-06-12
RU2493155C2 (ru) 2013-09-20
RU2009125672A (ru) 2011-01-20
AU2007328981B2 (en) 2013-07-11
IL198543A0 (en) 2010-02-17
US20080146565A1 (en) 2008-06-19
AU2007328981A1 (en) 2008-06-12
TW200831101A (en) 2008-08-01
WO2008068171A1 (en) 2008-06-12
BRPI0720003A2 (pt) 2018-09-18
KR20090075877A (ko) 2009-07-09
MX2009005508A (es) 2009-06-03
AR064133A1 (es) 2009-03-11
WO2008068171A9 (en) 2009-07-16
KR101152162B1 (ko) 2012-07-10
ZA200903495B (en) 2010-04-28
CN101547917A (zh) 2009-09-30
CL2007003502A1 (es) 2008-06-27
JP5179509B2 (ja) 2013-04-10

Similar Documents

Publication Publication Date Title
PE20081507A1 (es) Derivados de pirimidina como moduladores de jnk
PE20091236A1 (es) Derivados de pirimidina como immunomoduladores de tlr7
PE20081262A1 (es) Derivados de fenilo como moduladores de cinasas y composiciones
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20091033A1 (es) Derivados de nicotinamida como agentes anticancerosos y su preparacion
PE20090694A1 (es) Compuestos moduladores de sirtuinas
PE20110547A1 (es) Compuestos de isoindolina con actividad anticancerigena
PE20110285A1 (es) Derivados de sulfonamidofenil propionamida como ligandos del receptor vaniloide del subtipo 1
PE20090552A1 (es) Compuestos de pirimidina hidrazida como inhibidores de pgds
PE20130405A1 (es) Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
PE20080074A1 (es) Derivados de amida como agentes inhibidores de la quinasa c-fms
PL2240150T3 (pl) Kompozycje oftalmiczne z amfoterycznym środkiem powierzchniowo czynnym i kwasem hialuronowym
PE20071236A1 (es) Derivados de piperidinilo como moduladores de la actividad del receptor de quimiocina
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20121335A1 (es) Compuestos derivados de amida como inhibidores de raf cinasas
AR072904A1 (es) Compuestos de fenilamino-isonicotinamida y composiciones farmaceuticas que los contienen
PE20140408A1 (es) Derivados espiro-oxindol como antagonistas de mdm2
PE20091065A1 (es) Derivados bis-(sulfonilamino) en terapia 066
PE20091816A1 (es) Inhibidores de bace
CR10682A (es) Compuestos de tiazol pirazolopirimidina
PE20091436A1 (es) Derivados de sulfonamidas sustituidas como moduladores b1r
HRP20180285T1 (hr) Novi 4,6-disupstituirani derivati aminopirimidina
PE20080856A1 (es) Inhibidores de metaloproteasas de matriz
PE20091092A1 (es) Compuestos heterociclicos como inhibidores de la via hedgehog

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed